$ABIO in the news ---> Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks
Shares in Westminster, Colorado headquartered ARCA biopharma Inc. ended yesterday's session 3.43% lower at $0.54. The stock recorded a trading volume of 366,077 shares. The Company's shares are trading 1.95% below their 50-day moving average. Moreover, shares of ARCA biopharma, which focuses on developing genetically-targeted therapies for cardiovascular diseases, have an RSI of 47.06.
On May 29th, 2018, ARCA biopharma announced that data from the GENETIC-AF clinical trial was presented in a "Late Breaking Clinical Trials" oral presentation at the European Society of Cardiology Heart Failure 2018 World Congress on Sunday, May 27th, 2018. William T. Abraham, M.D., Professor of Medicine, Physiology and Cell Biology and Director, Division of Cardiovascular Medicine at the Ohio State University, presented the data. Wall St. Equities' downloadable research report on ABIO available at: